You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR OMNIPRED


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OMNIPRED

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00782717 ↗ A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients Completed Alcon Research Phase 2 2008-11-01 The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
NCT02229136 ↗ Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus Active, not recruiting Novartis Pharmaceuticals Phase 2 2014-09-04 This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis (mouth sores) in postmenopausal patients undergoing treatment with an aromatase inhibitor plus everolimus. An exploratory analysis will also evaluate patient response to next anti-cancer therapy of physician's choice following discontinuation of therapy with an aromatase inhibitor plus everolimus.
NCT02229136 ↗ Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus Active, not recruiting US Oncology Research Phase 2 2014-09-04 This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis (mouth sores) in postmenopausal patients undergoing treatment with an aromatase inhibitor plus everolimus. An exploratory analysis will also evaluate patient response to next anti-cancer therapy of physician's choice following discontinuation of therapy with an aromatase inhibitor plus everolimus.
NCT02373137 ↗ Descemet Endothelial Thickness Comparison Trial Active, not recruiting Stanford University Phase 4 2015-01-22 The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗ Descemet Endothelial Thickness Comparison Trial Active, not recruiting University of California, San Francisco Phase 4 2015-01-22 The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗ Descemet Endothelial Thickness Comparison Trial Active, not recruiting Oregon Health and Science University Phase 4 2015-01-22 The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗ Descemet Endothelial Thickness Comparison Trial Active, not recruiting Winston Chamberlain, MD, PhD Phase 4 2015-01-22 The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OMNIPRED

Condition Name

Condition Name for OMNIPRED
Intervention Trials
Transplantation, Corneal 1
Grafting, Corneal 1
Keratoplasty 1
Keratoplasty, Lamellar 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OMNIPRED
Intervention Trials
Diabetic Retinopathy 1
Stomatitis 1
Cataract 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OMNIPRED

Trials by Country

Trials by Country for OMNIPRED
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OMNIPRED
Location Trials
Oregon 1
California 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OMNIPRED

Clinical Trial Phase

Clinical Trial Phase for OMNIPRED
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OMNIPRED
Clinical Trial Phase Trials
Active, not recruiting 2
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OMNIPRED

Sponsor Name

Sponsor Name for OMNIPRED
Sponsor Trials
Alcon Research 1
Novartis Pharmaceuticals 1
US Oncology Research 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OMNIPRED
Sponsor Trials
Other 4
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.